Adar1 Capital Management portfolio · Q1 2026
ADAR1 Capital Management, LLC · CIK 0001940272 ·13F filings on SEC EDGAR
In Q1 2026, ADAR1 Capital Management, LLC reported 310 positions worth $1.7B. Its largest holding was ABVX at 9.1% of the portfolio, and the top 10 made up 40%. Its largest new position was BEAM ($34.5M), and it sold out of RNAM.
- NEW 82
- ADD 102
- REDUCE 60
- EXIT 42
Portfolio map
Each box is a position sized by its value. Color shows the change in shares from the previous quarter. The smallest 270 positions are grouped as one box.
Portfolio history
Q4 2025 to Q1 2026, 2 quarters
Weight of the largest holdings
The 7 holdings with the highest weight in any quarter shown, stacked with all others to 100%.
Holding timeline
Shade shows the weight in each quarter. A blank cell means the holding was not reported that quarter.
Holdings
Click a holding to see its price chart with the quarters the investor bought or sold.
| Name | Weight | Avg. cost (est.) | Latest price | Gain/loss | Value |
|---|---|---|---|---|---|
ABVX ABIVAX SA-ADR | 9.14% | $13.59 | $99.02 | +628.4% | $138M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PTGX PROTAGONIST THERAPEUTICS INC | 6.17% | $36.15* | $140.89 | +289.8% | $140.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ROIV ROIVANT SCIENCES LTD | 5.36% | $12.90* | $36.57 | +183.6% | $120.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMVT IMMUNOVANT INC | 3.92% | $19.64* | $33.78 | +72.0% | $90.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPY SS SPDR S&P 500 ETF TRUST-US | 2.91% | $647.31 | $762.63 | +17.8% | $57.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TERN TERNS PHARMACEUTICALS INC | 2.84% | $45.02 | $52.72 | +17.1% | $48.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CYTK CYTOKINETICS INC | 2.45% | $54.28* | $65.91 | +21.4% | $41.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRNX CRINETICS PHARMACEUTICALS IN | 2.44% | $38.22 | $37.42 | -2.1% | $42.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BOXX ALPHA ARCHITECT 1-3 MNTH BOX | 2.31% | $106.78 | $118.39 | +10.9% | $39.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DNLI DENALI THERAPEUTICS INC | 2.12% | $19.16 | $20.67 | +7.9% | $38.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BEAM BEAM THERAPEUTICS INC | 2.03% | $23.83 | $24.45 | +2.6% | $35.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ZLAB ZAI LAB LTD-ADR | 1.58% | $22.50* | $26.34 | +17.1% | $37.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SEPN SEPTERNA INC | 1.54% | $9.95 | $39.13 | +293.4% | $42.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VIR VIR BIOTECHNOLOGY INC | 1.45% | $8.96 | $11.18 | +24.8% | $30.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DBVT DBV TECHNOLOGIES SA-SPON ADR | 1.25% | $20.89 | $11.76 | -43.7% | $11.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVR ANTERIS TECHNOLOGIES GLOBAL | 1.24% | $5.36 | $7.77 | +45.0% | $29.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INSP INSPIRE MEDICAL SYSTEMS INC | 1.23% | $50.91 | $69.36 | +36.2% | $28.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SRRK SCHOLAR ROCK HOLDING CORP | 1.18% | $47.64 | $48.32 | +1.4% | $19.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RYTM RHYTHM PHARMACEUTICALS INC | 1.08% | $80.97 | $95.22 | +17.6% | $20.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SYRE SPYRE THERAPEUTICS INC | 1.00% | $46.92 | $89.03 | +89.7% | $30.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTMX CYTOMX THERAPEUTICS INC | 0.94% | $2.54 | $2.72 | +7.2% | $9.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRTA PROTHENA CORP PLC | 0.90% | $6.36 | $8.38 | +31.9% | $13.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SNY SANOFI-ADR | 0.90% | $48.01 | $41.23 | -14.1% | $13.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PCVX VAXCYTE INC | 0.89% | $38.43 | $56.90 | +48.1% | $14.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MNPR MONOPAR THERAPEUTICS INC | 0.85% | $49.36 | $79.67 | +61.4% | $21.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABUS ARBUTUS BIOPHARMA CORP | 0.83% | $3.83* | $4.78 | +24.9% | $15M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AMLX AMYLYX PHARMACEUTICALS INC | 0.82% | $4.89 | $29.10 | +495.4% | $29.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLDX CELLDEX THERAPEUTICS INC | 0.80% | $26.40 | $32.41 | +22.8% | $13.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TSHA TAYSHA GENE THERAPIES INC | 0.78% | $2.43* | $4.87 | +100.8% | $14.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XENE XENON PHARMACEUTICALS INC | 0.78% | $36.93 | $37.19 | +0.7% | $8.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STRO SUTRO BIOPHARMA INC | 0.77% | $23.20 | $16.11 | -30.6% | $8.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RVMD REVOLUTION MEDICINES INC | 0.77% | $45.37 | $205.26 | +352.4% | $27.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ELVN ENLIVEN THERAPEUTICS INC | 0.76% | $37.03 | $45.84 | +23.8% | $15.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CGON CG ONCOLOGY INC | 0.74% | $29.67 | $70.89 | +138.9% | $13.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BIL SS SPDR BB 1-3M T-BILL ETF | 0.73% | $91.43* | $91.64 | +0.2% | $12.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ESTA ESTABLISHMENT LABS HOLDINGS | 0.71% | $56.29 | $64.17 | +14.0% | $13.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
REPL REPLIMUNE GROUP INC | 0.71% | $5.89 | $13.24 | +124.9% | $21M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IVA INVENTIVA SA - ADR | 0.71% | $4.65 | $3.69 | -20.6% | $8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IONS IONIS PHARMACEUTICALS INC | 0.71% | $45.73 | $44.65 | -2.4% | $7.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NKTR NEKTAR THERAPEUTICS | 0.68% | $62.18 | $60.54 | -2.6% | $9.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IKT INHIBIKASE THERAPEUTICS INC | 0.65% | $2.80 | $2.06 | -26.7% | $13.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPRY ARS PHARMACEUTICALS INC | 0.64% | $8.94 | $4.31 | -51.8% | $5.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.62% | — | — | — | $10.5M | |
HLXC HELIX ACQUISITION CORP-CL A | 0.61% | $10.23 | $10.57 | +3.3% | $10.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OVID OVID THERAPEUTICS INC | 0.59% | $1.66* | $2.49 | +49.8% | $11.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OKUR ONKURE THERAPEUTICS INC-A | 0.59% | $3.62 | $2.72 | -24.8% | $6.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
REGN REGENERON PHARMACEUTICALS | 0.55% | $590.89 | $758.27 | +28.3% | $9.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MLTX MOONLAKE IMMUNOTHERAPEUTICS | 0.50% | $18.64 | $11.70 | -37.2% | $5.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LXEO LEXEO THERAPEUTICS INC | 0.50% | $6.67 | $3.38 | -49.3% | $5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRD OPUS GENETICS INC | 0.50% | $4.50 | $4.84 | +7.7% | $8.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
881624209 TEVA PHARMACEUTICAL INDS LTD | 0.48% | $16.77* | $33.88 | +102.1% | $9.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SVRA SAVARA INC | 0.47% | $2.86 | $5.16 | +80.4% | $7.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MPLT MAPLIGHT THERAPEUTICS INC | 0.45% | $20.33 | $10.19 | -49.9% | $3.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LONA LEONABIO INC | 0.44% | $8.75 | $3.57 | -59.2% | $2.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EQ EQUILLIUM INC | 0.44% | $1.43 | $1.62 | +13.6% | $6.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VKTX VIKING THERAPEUTICS INC | 0.44% | $31.86* | $32.60 | +2.3% | $7.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
36322Q206 DAMORA THERAPEUTICS INC | 0.43% | $25.90 | $26.01 | +0.4% | $7.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
URGN UROGEN PHARMA LTD | 0.42% | $19.24 | $40.63 | +111.2% | $16.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BBIO BRIDGEBIO PHARMA INC | 0.41% | $29.85* | $65.80 | +120.5% | $6.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRME PRIME MEDICINE INC | 0.40% | $3.48 | $3.05 | -12.2% | $6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.40% | — | — | — | $6.8M | |
VRTX VERTEX PHARMACEUTICALS INC | 0.40% | $424.09 | $522.81 | +23.3% | $7.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KRRO KORRO BIO INC | 0.36% | $11.32 | $9.91 | -12.5% | $5.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VRDN VIRIDIAN THERAPEUTICS INC | 0.35% | $18.26 | $20.59 | +12.8% | $6.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DHR DANAHER CORP | 0.35% | $222.14 | $221.55 | -0.3% | $6.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INSM INSMED INC | 0.34% | $163.52 | $114.14 | -30.2% | $4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
04351P101 ASCENDIS PHARMA A/S | 0.34% | $196.64* | $228.73 | +16.3% | $5.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BHF BRIGHTHOUSE FINANCIAL INC | 0.34% | $63.56 | $49.90 | -21.5% | $4.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SRPT SAREPTA THERAPEUTICS INC | 0.34% | $23.88* | $18.22 | -23.7% | $4.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OACCU OAKTREE ACQUISITION III LIFE | 0.32% | $10.14 | $10.89 | +7.4% | $5.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FRNM FREENOME INC | 0.32% | $10.14 | $10.88 | +7.3% | $5.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KRYS KRYSTAL BIOTECH INC | 0.30% | $181.75 | $332.56 | +83.0% | $6.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABOS ACUMEN PHARMACEUTICALS INC | 0.30% | $1.89 | $2.22 | +17.7% | $4.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IVVD INVIVYD INC | 0.29% | $1.10 | $0.87 | -20.9% | $3.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.29% | — | — | — | $4.9M | |
BHAVU BHAV ACQUISITION CORP | 0.29% | $9.97 | $10.15 | +1.8% | $5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TARA PROTARA THERAPEUTIC INC | 0.29% | $5.33 | $3.05 | -42.8% | $2.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.29% | — | — | — | $4.9M | |
| 0.29% | — | — | — | $4.9M | |
AGIO AGIOS PHARMACEUTICALS INC | 0.28% | $27.86 | $33.25 | +19.3% | $4.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LLY ELI LILLY & CO | 0.27% | $919.77 | $1,157.08 | +25.8% | $5.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DNTH DIANTHUS THERAPEUTICS INC | 0.27% | $83.92 | $88.05 | +4.9% | $4.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARWR ARROWHEAD PHARMACEUTICALS IN | 0.26% | $29.34* | $65.45 | +123.1% | $4.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BLTE BELITE BIO INC - ADR | 0.25% | $159.96 | $169.82 | +6.2% | $4.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EVMN EVOMMUNE INC | 0.25% | $17.12 | $8.26 | -51.8% | $1.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MLYS MINERALYS THERAPEUTICS INC | 0.25% | $23.08 | $25.13 | +8.9% | $3.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JANX JANUX THERAPEUTICS INC | 0.24% | $23.57 | $17.28 | -26.7% | $5.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLYM CLIMB BIO INC | 0.24% | $5.23 | $11.47 | +119.5% | $6.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PALI PALISADE BIO INC | 0.23% | $2.28 | $1.35 | -40.8% | $3.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AEXA AMERICAN EXCEPTIONALISM-CL A | 0.23% | $11.33 | $11.14 | -1.6% | $4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPRB SPRUCE BIOSCIENCES INC | 0.23% | $86.89 | $48.58 | -44.1% | $2.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NAMS NEWAMSTERDAM PHARMA CO NV | 0.22% | $18.89 | $24.32 | +28.7% | $2.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LQDAPut LIQUIDIA CORP | 0.22% | — | — | — | $3.8M |
ZURA ZURA BIO LTD | 0.22% | $3.63 | $4.16 | +14.7% | $2.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACLX ARCELLX INC | 0.22% | $77.65 | $114.82 | +47.9% | $3.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTNM CONTINEUM THERAPEUTICS INC-A | 0.21% | $11.30 | $13.42 | +18.8% | $3.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.21% | — | — | — | $3.6M | |
GLUE MONTE ROSA THERAPEUTICS INC | 0.21% | $7.41 | $11.93 | +61.0% | $2.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ONC BEONE MEDICINES LTD-ADR | 0.20% | $296.97 | $365.94 | +23.2% | $4.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TENX TENAX THERAPEUTICS INC | 0.20% | $13.16 | $56.70 | +330.8% | $12.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVBP ARRIVENT BIOPHARMA INC | 0.19% | $23.07 | $23.07 | 0.0% | $3.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PLRX PLIANT THERAPEUTICS INC | 0.19% | $1.26 | $1.08 | -14.2% | $2.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ATAI ATAIBECKLEY INC | 0.19% | $3.54 | $5.27 | +48.9% | $4.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RLMD RELMADA THERAPEUTICS INC | 0.19% | $6.81 | $3.77 | -44.7% | $1.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CATX PERSPECTIVE THERAPEUTICS INC | 0.18% | $3.99 | $2.75 | -31.1% | $2.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRBP CORBUS PHARMACEUTICALS HOLDI | 0.18% | $8.45 | $6.82 | -19.3% | $2.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ELDN ELEDON PHARMACEUTICALS INC | 0.18% | $1.51 | $2.53 | +67.5% | $2.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PHVS PHARVARIS NV | 0.18% | $24.56 | $31.72 | +29.1% | $3.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
APLS APELLIS PHARMACEUTICALS INC | 0.17% | $42.83 | $40.23 | -6.1% | $2.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EWTX EDGEWISE THERAPEUTICS INC | 0.17% | $21.62 | $40.60 | +87.8% | $3.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PEPG PEPGEN INC | 0.17% | $1.79 | $2.42 | +34.8% | $3.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CAPR CAPRICOR THERAPEUTICS INC | 0.16% | $30.40 | $37.88 | +24.6% | $3.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MASI MASIMO CORP | 0.16% | $147.55 | $177.87 | +20.5% | $2.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INO INOVIO PHARMACEUTICALS INC | 0.15% | $1.74 | $1.83 | +5.2% | $2.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TFX TELEFLEX INC | 0.15% | $122.04 | $125.04 | +2.5% | $2.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DRUG BRIGHT MINDS BIOSCIENCES INC | 0.15% | $73.49 | $49.82 | -32.2% | $1.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BIOA BIOAGE LABS INC | 0.14% | $4.07 | $7.09 | +74.1% | $961.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALEC ALECTOR INC | 0.13% | $1.56 | $1.85 | +18.6% | $1.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PFE PFIZER INC | 0.13% | $26.49* | $28.52 | +7.7% | $2.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DCTH DELCATH SYSTEMS INC | 0.12% | $6.94* | $15.97 | +130.1% | $3.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BIIB BIOGEN INC | 0.12% | $155.57 | $225.88 | +45.2% | $2.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTB CONNECT BIOPHARMA HOLDINGS L | 0.11% | $2.62 | $1.10 | -58.0% | $816.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XBIPut SS SPDR S&P BIOTECH ETF | 0.11% | — | — | — | $1.9M |
SMMT SUMMIT THERAPEUTICS INC | 0.10% | $20.73 | $16.91 | -18.4% | $1.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GMED GLOBUS MEDICAL INC - A | 0.10% | $87.31 | $74.90 | -14.2% | $1.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALKS ALKERMES PLC | 0.10% | $28.78 | $40.52 | +40.8% | $1.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.10% | — | — | — | $1.6M | |
SLNO SOLENO THERAPEUTICS INC | 0.09% | $47.61 | $33.48 | -29.7% | $1.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CCIIU COHEN CIRCLE ACQUISITION COR | 0.09% | $10.28 | $10.46 | +1.8% | $1.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RCKT ROCKET PHARMACEUTICALS INC | 0.09% | $6.85 | $2.63 | -61.6% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
868459108 SUPERNUS PHARMACEUTICALS | 0.09% | $48.77 | $43.04 | -11.8% | $1.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTA CENTESSA PHARMACEUTICALS LTD | 0.09% | $14.81 | $39.72 | +168.1% | $1.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FOLD AMICUS THERAPEUTICS INC | 0.09% | $14.46 | $14.46 | 0.0% | $1.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MAZE MAZE THERAPEUTICS INC | 0.09% | $39.18 | $27.18 | -30.6% | $1.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
UNH UNITEDHEALTH GROUP INC | 0.09% | $270.59 | $367.08 | +35.7% | $2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ADGM ADAGIO MEDICAL HOLDINGS INC | 0.08% | $1.04 | $0.15 | -85.3% | $184.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FWRD FORWARD AIR CORP | 0.08% | $19.53 | $13.51 | -30.8% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SXT SENSIENT TECHNOLOGIES CORP | 0.08% | $86.44 | $130.72 | +51.2% | $2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KNSA KINIKSA PHARMACEUTICALS INTE | 0.08% | $28.05 | $74.61 | +166.0% | $2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRVS CORVUS PHARMACEUTICALS INC | 0.08% | $7.70 | $11.52 | +49.6% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MSLE SATELLOS BIOSCIENCE INC | 0.07% | $5.63 | $8.50 | +51.0% | $1.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
QURE UNIQURE NV | 0.07% | $43.46 | $24.16 | -44.4% | $1.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NVO NOVO-NORDISK A/S-SPONS ADR | 0.07% | $36.75 | $37.91 | +3.2% | $1.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PMN PROMIS NEUROSCIENCES INC | 0.07% | $12.70 | $10.52 | -17.2% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LXRX LEXICON PHARMACEUTICALS INC | 0.07% | $1.56 | $1.88 | +20.2% | $1.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SDGR SCHRODINGER INC | 0.07% | $11.36 | $31.05 | +173.3% | $3.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.07% | — | — | — | $1.1M | |
XNCR XENCOR INC | 0.07% | $13.66 | $24.95 | +82.7% | $2.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OABI OMNIAB INC | 0.07% | $1.99* | $2.46 | +23.4% | $1.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FDMT 4D MOLECULAR THERAPEUTICS IN | 0.06% | $7.67 | $14.31 | +86.6% | $1.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KROS KEROS THERAPEUTICS INC | 0.06% | $11.37* | $11.40 | +0.3% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DAWN DAY ONE BIOPHARMACEUTICALS I | 0.06% | $21.44 | $21.44 | 0.0% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BMY BRISTOL-MYERS SQUIBB CO | 0.06% | $53.94 | $62.40 | +15.7% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TNGX TANGO THERAPEUTICS INC | 0.06% | $8.86 | $24.95 | +181.6% | $1.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TNYA TENAYA THERAPEUTICS INC | 0.06% | $0.71 | $0.60 | -15.2% | $910.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BSAAU BEST SPAC I ACQUISITION CORP | 0.06% | $10.04 | $10.40 | +3.6% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MCK MCKESSON CORP | 0.06% | $820.29 | $853.81 | +4.1% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BMRN BIOMARIN PHARMACEUTICAL INC | 0.06% | $61.61 | $60.00 | -2.6% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
04280AAC4 ARROWHEAD PHARMACEUTICALS IN | 0.06% | $102.40 | $102.40 | 0.0% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ORKA ORUKA THERAPEUTICS INC | 0.06% | $10.33 | $83.29 | +706.6% | $1.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EA ELECTRONIC ARTS INC | 0.06% | $201.70 | $205.04 | +1.7% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FULC FULCRUM THERAPEUTICS INC | 0.06% | $10.51* | $3.70 | -64.8% | $483.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCRX BIOCRYST PHARMACEUTICALS INC | 0.06% | $8.78 | $8.33 | -5.2% | $874.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GH GUARDANT HEALTH INC | 0.05% | $75.41 | $178.36 | +136.5% | $1.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CBIO CRESCENT BIOPHARMA INC | 0.05% | $11.86 | $14.59 | +23.0% | $733.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTX CONTEXT THERAPEUTICS INC | 0.05% | $1.81 | $0.30 | -83.4% | $105.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
29286M105 ENGENE HOLDINGS INC | 0.05% | $9.03 | $6.81 | -24.6% | $910.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SLN SILENCE THERAPEUTICS PLC-ADR | 0.05% | $6.99* | $10.93 | +56.4% | $1.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARE ALEXANDRIA REAL ESTATE EQUIT | 0.05% | $48.53 | $47.46 | -2.2% | $925.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KVACFCall KEEN VISION ACQUISITION CORP | 0.05% | — | — | — | $900K |
IBIO IBIO INC | 0.05% | $1.86 | $1.18 | -36.5% | $554.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BNTX BIONTECH SE-ADR | 0.05% | $98.62 | $98.30 | -0.3% | $983K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GILD GILEAD SCIENCES INC | 0.05% | $122.74 | $149.05 | +21.4% | $946.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NRIX NURIX THERAPEUTICS INC | 0.05% | $16.89 | $23.71 | +40.3% | $1.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DYN DYNE THERAPEUTICS INC | 0.05% | $12.87 | $16.11 | +25.2% | $764.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ISRG INTUITIVE SURGICAL INC | 0.05% | $519.72 | $406.63 | -21.8% | $744.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ANL ADLAI NORTYE GROUP LTD | 0.05% | $6.92 | $16.00 | +131.2% | $1.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
WW WW INTERNATIONAL INC-NEW | 0.05% | $27.37 | $15.46 | -43.5% | $892K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RNA ATRIUM THERAPEUTICS INC | 0.05% | $13.37 | $8.28 | -38.1% | $477.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ITGR INTEGER HOLDINGS CORP | 0.05% | $88.00 | $126.35 | +43.6% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.05% | — | — | — | $765K | |
KPTI KARYOPHARM THERAPEUTICS INC | 0.04% | $6.07 | $9.77 | +60.8% | $1.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CMPX COMPASS THERAPEUTICS INC | 0.04% | $4.54 | $1.04 | -77.1% | $144.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NUVL NUVALENT INC-A | 0.04% | $76.68 | $123.50 | +61.1% | $857.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CGEM CULLINAN THERAPEUTICS INC | 0.04% | $10.35 | $15.35 | +48.3% | $767.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IDYA IDEAYA BIOSCIENCES INC | 0.04% | $27.21 | $38.42 | +41.2% | $768.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.04% | — | — | — | $654K | |
ENTA ENANTA PHARMACEUTICALS INC | 0.04% | $15.16 | $13.18 | -13.1% | $676.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VERA VERA THERAPEUTICS INC | 0.04% | $49.80 | $32.29 | -35.2% | $517.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
92941V308 VYNE THERAPEUTICS INC | 0.04% | $0.59 | $0.65 | +9.7% | $692.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BSX BOSTON SCIENTIFIC CORP | 0.04% | $79.05 | $43.65 | -44.8% | $436.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVTR AVANTOR INC | 0.04% | $11.45 | $15.05 | +31.5% | $1.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARVN ARVINAS INC | 0.04% | $7.02 | $7.74 | +10.2% | $445.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KZR KEZAR LIFE SCIENCES INC | 0.04% | $0.77 | $7.42 | +859.6% | $607.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KLRS KALARIS THERAPEUTICS INC | 0.03% | $8.44 | $2.89 | -65.8% | $289K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MIRM MIRUM PHARMACEUTICALS INC | 0.03% | $92.38 | $85.48 | -7.5% | $530K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JAZZ JAZZ PHARMACEUTICALS PLC | 0.03% | $150.04 | $231.52 | +54.3% | $694.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ASMB ASSEMBLY BIOSCIENCES INC | 0.03% | $25.96 | $23.49 | -9.5% | $468.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRLD PRELUDE THERAPEUTICS INC | 0.03% | $3.42 | $3.91 | +14.3% | $597.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GTERU GLOBA TERRA ACQUISITION CORP | 0.03% | $10.17 | $10.46 | +2.9% | $523K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
USFR WISDOMTREE FLOATING RATE TRE | 0.03% | $50.24* | $50.39 | +0.3% | $503.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACRS ACLARIS THERAPEUTICS INC | 0.03% | $2.33 | $5.26 | +125.3% | $696.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRAX PRAXIS PRECISION MEDICINES I | 0.03% | $294.74 | $291.23 | -1.2% | $436.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LUNG PULMONX CORP | 0.03% | $2.35 | $1.91 | -18.9% | $715.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ELAN ELANCO ANIMAL HEALTH INC | 0.03% | $22.63 | $22.39 | -1.1% | $447.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.03% | — | — | — | $477.8K | |
PHAT PHATHOM PHARMACEUTICALS INC | 0.03% | $8.62 | $7.30 | -15.3% | $313.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MDGL MADRIGAL PHARMACEUTICALS INC | 0.03% | $431.22 | $503.96 | +16.9% | $451K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PYPD POLYPID LTD | 0.03% | $4.34 | $5.27 | +21.4% | $547.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BABA ALIBABA GROUP HOLDING-SP ADR | 0.03% | $178.73 | $107.54 | -39.8% | $384.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CORZ CORE SCIENTIFIC INC | 0.03% | $14.56 | $15.98 | +9.8% | $479.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
WHWK WHITEHAWK THERAPEUTICS INC | 0.03% | $2.83 | $3.76 | +33.0% | $483.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NTRA NATERA INC | 0.03% | $229.09 | $413.31 | +80.4% | $887.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VTGN VISTAGEN THERAPEUTICS INC | 0.03% | $0.95 | $0.23 | -76.1% | $169.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TXMD THERAPEUTICSMD INC | 0.02% | $2.25* | $2.03 | -9.8% | $424.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.02% | — | — | — | $419K | |
SNDX SYNDAX PHARMACEUTICALS INC | 0.02% | $21.75 | $18.80 | -13.6% | $329K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TECX TECTONIC THERAPEUTIC INC | 0.02% | $17.04 | $23.29 | +36.7% | $302.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TRDA ENTRADA THERAPEUTICS INC | 0.02% | $12.62 | $6.35 | -49.7% | $193.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BHVN BIOHAVEN LTD | 0.02% | $15.94 | $13.35 | -16.2% | $597.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MRK MERCK & CO. INC. | 0.02% | $82.12 | $145.31 | +77.0% | $456.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VSTM VERASTEM INC | 0.02% | $5.30 | $8.05 | +51.9% | $572.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.02% | — | — | — | $372.8K | |
RGNX REGENXBIO INC | 0.02% | $8.79 | $8.38 | -4.7% | $372.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACET ADICET BIO INC | 0.02% | $8.42 | $7.14 | -15.2% | $384.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LEGN LEGEND BIOTECH CORP-ADR | 0.02% | $18.09 | $19.89 | +10.0% | $397.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SRZN SURROZEN INC | 0.02% | $29.13 | $32.18 | +10.5% | $386.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ZNTL ZENTALIS PHARMACEUTICALS INC | 0.02% | $1.73 | $2.77 | +60.4% | $400.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCYC BICYCLE THERAPEUTICS PLC-ADR | 0.02% | $4.64 | $3.68 | -20.7% | $262.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NBIX NEUROCRINE BIOSCIENCES INC | 0.02% | $131.74 | $141.84 | +7.7% | $354.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.02% | — | — | — | $328.7K | |
Y95308105 WAVE LIFE SCIENCES LTD | 0.02% | $7.25 | $5.81 | -19.9% | $260.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KURA KURA ONCOLOGY INC | 0.02% | $7.31 | $10.71 | +46.6% | $428.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KPRX KIORA PHARMACEUTICALS INC | 0.02% | $4.11 | $2.56 | -37.7% | $429.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CORT CORCEPT THERAPEUTICS INC | 0.02% | $40.31 | $115.23 | +185.9% | $921.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
UPB UPSTREAM BIO INC | 0.02% | $9.00 | $9.00 | 0.0% | $315K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KIDS ORTHOPEDIATRICS CORP | 0.02% | $17.76 | $19.13 | +7.7% | $379.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ANNX ANNEXON INC | 0.02% | $5.09 | $5.54 | +8.9% | $304.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GERN GERON CORP | 0.02% | $3.20* | $1.23 | -61.6% | $246K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JD JD.COM INC-ADR | 0.02% | $34.98 | $26.60 | -24.0% | $266K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PMVP PMV PHARMACEUTICALS INC | 0.02% | $1.38 | $1.67 | +20.9% | $385.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TRAW TRAWS PHARMA INC | 0.02% | $1.13 | $0.59 | -47.5% | $91.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JBIO JADE BIOSCIENCES INC | 0.02% | $15.43 | $14.05 | -8.9% | $281K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RARE ULTRAGENYX PHARMACEUTICAL IN | 0.02% | $20.95 | $15.03 | -28.3% | $201.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PCAPU PROCAP ACQUISITION CORP | 0.02% | $10.59 | $10.48 | -1.0% | $282.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCAX BICARA THERAPEUTICS INC | 0.02% | $9.29 | $18.61 | +100.3% | $255.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RXST RXSIGHT INC | 0.02% | $5.21 | $4.90 | -5.9% | $211.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PANW PALO ALTO NETWORKS INC | 0.02% | $160.32 | $397.31 | +147.8% | $635.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NTLA INTELLIA THERAPEUTICS INC | 0.01% | $12.82 | $12.06 | -5.9% | $235.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRWD CROWDSTRIKE HOLDINGS INC - A | 0.01% | $390.41 | $1,059.00 | +171.3% | $677.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RBRK RUBRIK INC-A | 0.01% | $48.97 | $114.47 | +133.8% | $560.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RPRX ROYALTY PHARMA PLC- CL A | 0.01% | $47.97 | $58.36 | +21.7% | $291.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SGRY SURGERY PARTNERS INC | 0.01% | $23.75 | $16.80 | -29.3% | $336K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LRMR LARIMAR THERAPEUTICS INC | 0.01% | $2.89 | $3.19 | +10.6% | $168.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EOLS EVOLUS INC | 0.01% | $5.74 | $8.00 | +39.4% | $446.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
QTTB Q32 BIO INC | 0.01% | $4.65 | $8.27 | +77.9% | $289.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
54303L203 LONGEVERON INC | 0.01% | $1.04 | $0.70 | -32.4% | $140.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ANAB ANAPTYSBIO INC | 0.01% | $55.46 | $50.26 | -9.4% | $185.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CEPS CANTOR EQUITY PARTNERS VI -A | 0.01% | $10.10 | $10.20 | +1.0% | $204K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KALV KALVISTA PHARMACEUTICALS INC | 0.01% | $9.79 | $20.13 | +105.7% | $201.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KYTX KYVERNA THERAPEUTICS INC | 0.01% | $9.40 | $8.63 | -8.2% | $193.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NUVB NUVATION BIO INC | 0.01% | $4.29 | $5.60 | +30.5% | $243.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BNTC BENITEC BIOPHARMA INC | 0.01% | $10.65 | $10.00 | -6.1% | $175K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LPCN LIPOCINE INC | 0.01% | $7.99 | $7.99 | 0.0% | $185.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RLYB RALLYBIO CORP | 0.01% | $8.97 | $17.20 | +91.8% | $353.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RZLT REZOLUTE INC | 0.01% | $3.87 | $4.14 | +6.9% | $242.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
QCLS Q/C TECHNOLOGIES INC | 0.01% | $3.45 | $3.90 | +13.0% | $195K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ERAS ERASCA INC | 0.01% | $16.18 | $14.66 | -9.4% | $146.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
COYA COYA THERAPEUTICS INC | 0.01% | $3.94 | $5.01 | +27.2% | $204.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PSNL PERSONALIS INC | 0.01% | $6.37 | $16.28 | +155.6% | $407K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SIBN SI-BONE INC | 0.01% | $12.63 | $18.80 | +48.9% | $236.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STLN STARLING ONCOLOGY INC | 0.01% | $3.07 | $6.32 | +105.9% | $316K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
23256X407 CYBIN INC | 0.01% | $7.86 | $12.29 | +56.4% | $384.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STIM NEURONETICS INC | 0.01% | $1.45 | $2.34 | +61.4% | $234K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARDX ARDELYX INC | 0.01% | $5.99 | $3.42 | -42.9% | $81.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IFRX INFLARX NV | 0.01% | $0.89 | $1.80 | +101.3% | $284.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACHV ACHIEVE LIFE SCIENCES INC | 0.01% | $2.95 | $8.09 | +174.0% | $386.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VYGR VOYAGER THERAPEUTICS INC | 0.01% | $5.94* | $2.68 | -54.9% | $93.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CMMB CHEMOMAB THERAPEUTICS LTD | 0.01% | $1.65 | $1.62 | -1.8% | $129.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
471871202 JASPER THERAPEUTICS INC | 0.01% | $1.83 | $0.42 | -77.0% | $58.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NEUP NEUPHORIA THERAPEUTICS INC | 0.01% | $3.88 | $3.56 | -8.2% | $106.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MIST MILESTONE PHARMACEUTICALS IN | 0.01% | $2.02 | $0.87 | -57.1% | $86.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARCT ARCTURUS THERAPEUTICS HOLDIN | 0.01% | $7.72 | $13.69 | +77.3% | $205.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MGNX MACROGENICS INC | 0.01% | $2.89 | $3.86 | +33.6% | $154.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CCCC C4 THERAPEUTICS INC | 0.01% | $2.63 | $3.33 | +26.6% | $143.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RXRX RECURSION PHARMACEUTICALS-A | 0.01% | $5.72 | $4.13 | -27.7% | $144.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DSGN DESIGN THERAPEUTICS INC | 0.01% | $10.64 | $12.57 | +18.1% | $125.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
38341P102 GOSSAMER BIO INC | 0.01% | $0.77* | $0.16 | -78.5% | $47.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMMX IMMIX BIOPHARMA INC | 0.01% | $5.23 | $9.11 | +74.2% | $91.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STICall SOLIDION TECHNOLOGY INC | 0.01% | — | — | — | $85.2K |
LITS LITE STRATEGY INC | 0.00% | $2.42 | $1.32 | -45.5% | $88.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VERU VERU INC | 0.00% | $2.14 | $2.66 | +24.3% | $93.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KYNB KYNTRA BIO INC | 0.00% | $8.78 | $6.65 | -24.3% | $69.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLOV CLOVER HEALTH INVESTMENTS CO | 0.00% | $3.05 | $4.31 | +41.5% | $172.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BMEA BIOMEA FUSION INC | 0.00% | $1.24 | $1.33 | +7.3% | $57.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NMRA NEUMORA THERAPEUTICS INC | 0.00% | $1.79 | $0.60 | -66.7% | $19.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OGN ORGANON & CO | 0.00% | $9.47 | $13.70 | +44.6% | $137K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ESPR ESPERION THERAPEUTICS INC | 0.00% | $2.74 | $3.16 | +15.3% | $67.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MREO MEREO BIOPHARMA GROUP PL-ADR | 0.00% | $0.42 | $0.33 | -20.8% | $49.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ANTX AN2 THERAPEUTICS INC | 0.00% | $3.42 | $5.32 | +55.6% | $73.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ASPCR A SPAC III ACQUISITION CORP | 0.00% | $0.14 | $0.10 | -28.4% | $21.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AQST AQUESTIVE THERAPEUTICS INC | 0.00% | $4.15 | $4.15 | 0.0% | $41.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
002120202 ATYR PHARMA INC | 0.00% | $0.72 | $0.60 | -17.3% | $30.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
09077B104 BIOATLA INC | 0.00% | $0.49 | $0.16 | -67.0% | $36.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
483119202 KALA BIO INC | 0.00% | — | $0.17 | — | $24.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CHRS COHERUS ONCOLOGY INC | 0.00% | $0.73 | $1.21 | +65.5% | $12.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRQR PROQR THERAPEUTICS NV | 0.00% | $5.30 | $1.66 | -68.7% | $16.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
22053A107 QUINCE THERAPEUTICS INC | 0.00% | $1.28 | $0.10 | -92.1% | $5.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.00% | — | — | — | $5.1K | |
4525EP101 IMMUNIC INC | 0.00% | — | — | — | $0 |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price. * Held since before Dec 31, 2023, when our collected history starts, so the average starts from that quarter's price.
Changes in shares
Change in shares held vs Dec 31, 2025, for the 20 largest positions that changed. Bars are capped at ±100%; the label shows the actual change.
Sold out this quarter
Held on Dec 31, 2025 and not reported for Q1 2026.
| Stock | Prior weight | Prior shares | Prior value | Change |
|---|---|---|---|---|
| RNAM AVIDITY BIOSCIENCES INC | 2.90% | 546,534 | $39.4M | EXIT |
| RAPT RAPT THERAPEUTICS INC | 1.27% | 509,679 | $17.3M | EXIT |
| CDTX CIDARA THERAPEUTICS INC | 0.97% | 59,677 | $13.2M | EXIT |
| AAM AA MISSION ACQUISITION COR-A | 0.45% | 578,359 | $6.2M | EXIT |
| AAMCall AA MISSION ACQUISITION COR-A | 0.32% | 405,089 | $4.3M | EXIT |
| N0731H103 ATAI BECKLEY NV | 0.27% | 913,242 | $3.7M | EXIT |
| AVDL AVADEL PHARMACEUTICALS LTD | 0.24% | 150,532 | $3.2M | EXIT |
| IWM ISHARES RUSSELL 2000 ETF | 0.22% | 12,070 | $3M | EXIT |
| BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 0.21% | 226,248 | $2.8M | EXIT |
| DVAX DYNAVAX TECHNOLOGIES CORP | 0.19% | 170,000 | $2.6M | EXIT |
| ATXS ASTRIA THERAPEUTICS INC | 0.17% | 173,557 | $2.3M | EXIT |
| GRCE GRACE THERAPEUTICS INC | 0.16% | 641,988 | $2.2M | EXIT |
| OLMA OLEMA PHARMACEUTICALS INC | 0.15% | 81,399 | $2M | EXIT |
| AQSTPut AQUESTIVE THERAPEUTICS INC | 0.12% | 254,000 | $1.6M | EXIT |
| 38341P102Put GOSSAMER BIO INC | 0.11% | 463,200 | $1.4M | EXIT |
| OMERPut OMEROS CORP | 0.09% | 75,000 | $1.3M | EXIT |
| INFQ INFLEQTION INC | 0.07% | 64,887 | $1M | EXIT |
| URGNCall UROGEN PHARMA LTD | 0.07% | 40,000 | $936.8K | EXIT |
| UTHR UNITED THERAPEUTICS CORP | 0.07% | 1,900 | $925.8K | EXIT |
| PLYM PLYMOUTH INDUSTRIAL REIT INC | 0.07% | 41,065 | $898.5K | EXIT |
| QNRX QUOIN PHARMACEUTICALS LT-ADR | 0.06% | 58,230 | $840.3K | EXIT |
| 046353108 ASTRAZENECA PLC | 0.06% | 9,000 | $827.4K | EXIT |
| VTYX VENTYX BIOSCIENCES INC | 0.05% | 81,600 | $736.8K | EXIT |
| FULCCall FULCRUM THERAPEUTICS INC | 0.05% | 65,000 | $735.2K | EXIT |
| NGNE NEUROGENE INC | 0.05% | 30,633 | $631K | EXIT |
| NVCR NOVOCURE LTD | 0.03% | 34,000 | $439.6K | EXIT |
| OMER OMEROS CORP | 0.03% | 25,000 | $429.4K | EXIT |
| CTMXCall CYTOMX THERAPEUTICS INC | 0.03% | 100,000 | $426K | EXIT |
| AUPH AURINIA PHARMACEUTICALS INC | 0.03% | 22,000 | $350.9K | EXIT |
| DAY DAYFORCE INC | 0.03% | 5,000 | $345.8K | EXIT |
| IDXX IDEXX LABORATORIES INC | 0.02% | 400 | $270.6K | EXIT |
| SPRO SPERO THERAPEUTICS INC | 0.02% | 113,839 | $265.2K | EXIT |
| DYNCall DYNE THERAPEUTICS INC | 0.01% | 10,000 | $195.6K | EXIT |
| OTLKPut OUTLOOK THERAPEUTICS INC | 0.01% | 100,000 | $158K | EXIT |
| 184492106 CLEANCORE SOLUTIONS INC | 0.01% | 521,980 | $135.7K | EXIT |
| INOCall INOVIO PHARMACEUTICALS INC | 0.01% | 75,500 | $131.4K | EXIT |
| GBIO GENERATION BIO CO | 0.01% | 22,144 | $125.8K | EXIT |
| 38341P102Call GOSSAMER BIO INC | 0.01% | 35,100 | $108.8K | EXIT |
| SABS SAB BIOTHERAPEUTICS INC | 0.01% | 26,344 | $98.5K | EXIT |
| VTGNPut VISTAGEN THERAPEUTICS INC | 0.01% | 120,000 | $79.4K | EXIT |
| 44984F807 INVO FERTILITY INC. | 0.00% | 26,722 | $20.1K | EXIT |
| IOBTQ IO BIOTECH INC | 0.00% | 24,964 | $15.2K | EXIT |
SEC filings for Q1 2026
- 13F-HR 0001940272-26-000005 · accepted May 16, 2026, 00:25 UTC